Cerebral Cortex, Vol. 11, No. 8, 728-733,
August 2001
© 2001 Oxford University Press
The Cannabinoid Receptor Agonist WIN 55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex: an In Vivo and In Vitro Study
Department of Clinical and Experimental Medicine, Pharmacology Section, University of Ferrara, Ferrara and , 1 Department of Neuroscience, University of Cagliari, Cagliari, Italy
The effects of the cannabinoid receptor agonist WIN 55,212-2 on endogenous extracellular glutamate levels in the prefrontal cortex of the awake rat and in primary cultures of rat cerebral cortex neurons were investigated. In the prefrontal cortex WIN 55,212-2 (0.1 and 1 mg/kg i.p.) increased dialysate glutamate levels from of the awake rat, while the lower (0.01 mg/kg) and the higher (2 mg/kg) doses were ineffective. Furthermore, the WIN 55,212-2 (0.1 mg/kg)- induced increase of dialysate glutamate levels was counteracted by pretreatment with the selective CB1 receptor antagonist SR141716A (0.1 mg/kg i.p.) and by the local perfusion with a low-calcium Ringer solution (Ca2+ 0.2 mM). In primary cultures of rat cerebral cortex neurons, WIN 55,212-2 (0.01–100 nM) increased extracellular glutamate levels, displaying a bell-shaped concentration–response curve. The facilitatory effect of WIN 55,212-2 (1 nM) was fully counteracted by SR141716A (10 nM), by the replacement of the normal Krebs Ringer-bicarbonate buffer with a low Ca2+ medium (0.2 mM) and by the IP3 receptor antagonist xestospongin C (1 µM). These in vivo and in vitro findings suggest an increase in cortical glutamatergic transmission by CB1 receptors, an effect that may underlie some of the psychoactive and behavioural actions of acute exposure to marijuana.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Fortin and E. S. Levine Differential Effects of Endocannabinoids on Glutamatergic and GABAergic Inputs to Layer 5 Pyramidal Neurons Cereb Cortex, January 1, 2007; 17(1): 163 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Antonelli, M. C. Tomasini, M. Tattoli, T. Cassano, S. Tanganelli, S. Finetti, E. Mazzoni, L. Trabace, L. Steardo, V. Cuomo, et al. Prenatal Exposure to the CB1 Receptor Agonist WIN 55,212-2 Causes Learning Disruption Associated with Impaired Cortical NMDA Receptor Function and Emotional Reactivity Changes in Rat Offspring Cereb Cortex, December 1, 2005; 15(12): 2013 - 2020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mereu, M. Fa, L. Ferraro, R. Cagiano, T. Antonelli, M. Tattoli, V. Ghiglieri, S. Tanganelli, G. L. Gessa, and V. Cuomo Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release PNAS, April 15, 2003; 100(8): 4915 - 4920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Rawls, A. Cowan, R. J. Tallarida, E. B. Geller, and M. W. Adler N-Methyl-D-aspartate Antagonists and WIN 55212-2 [4,5-Dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin-6-one], a Cannabinoid Agonist, Interact to Produce Synergistic Hypothermia J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 395 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Ploner, A. Tschirch, F. Ostendorf, S. Dick, B. M. Gaymard, S. Rivaud-Pechoux, F. Sporkert, F. Pragst, and A. M. Stadelmann Oculomotor Effects of {delta}-9-Tetrahydrocannabinol in Humans: Implications for the Functional Neuroanatomy of the Brain Cannabinoid System Cereb Cortex, October 1, 2002; 12(10): 1016 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202. [Abstract] [Full Text] [PDF]
|
|